Short Interest in Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Expands By 148.7%

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) was the target of a large increase in short interest during the month of February. As of February 15th, there was short interest totalling 1,570,000 shares, an increase of 148.7% from the January 31st total of 631,300 shares. Based on an average daily trading volume, of 6,310,000 shares, the days-to-cover ratio is currently 0.2 days. Approximately 8.7% of the shares of the stock are short sold.

Virpax Pharmaceuticals Stock Performance

Shares of VRPX stock opened at $0.24 on Friday. Virpax Pharmaceuticals has a twelve month low of $0.22 and a twelve month high of $5.48. The business has a fifty day simple moving average of $0.32 and a 200 day simple moving average of $0.53.

Institutional Trading of Virpax Pharmaceuticals

An institutional investor recently bought a new position in Virpax Pharmaceuticals stock. Garden State Investment Advisory Services LLC acquired a new position in shares of Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 57,300 shares of the company’s stock, valued at approximately $40,000. Garden State Investment Advisory Services LLC owned about 1.17% of Virpax Pharmaceuticals as of its most recent SEC filing. Hedge funds and other institutional investors own 32.23% of the company’s stock.

Virpax Pharmaceuticals Company Profile

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.